eHealth in pediatric respiratory allergy

2024-9-13

Allergen immunotherapy and eosinophilic esophagitis: friends or foes?

2024-9-13

Real-world evidence of allergen immunotherapy

2024-8-30

The collaborative medical practice of the ocular surface: a major role of the allergist/immunologist

2024-8-29

Anaphylaxis: glimpse into the future, attention to the present

2024-8-29

Editorial introductions

2024-8-29

Integrative therapeutics for ocular surface disorders

2024-8-14

Innate lymphoid cells in immunoglobulin E-mediated food allergy

2024-8-13

Ocular surface disorders: office procedures for the allergist/clinical immunologist

2024-8-12

Hymenoptera venom allergy in children and adolescents

2024-8-12

The risk of anaphylaxis on holidays

2024-8-2

Chronic urticaria: not only after COVID-19 vaccination

2024-7-30

Evidence-based use of epinephrine in anaphylaxis

2024-7-29

Tryptase in drug-induced anaphylaxis: the need for acute and baseline values

2024-7-25

Artificial intelligence and machine learning for anaphylaxis algorithms

2024-7-24

The evolution of cyclosporine treatments for treatment of ocular surface diseases

2024-7-24

Beyond the appearances: exploring complexities in anaphylaxis differential diagnosis

2024-7-24

Novel therapeutic receptor agonists and antagonists in allergic conjunctivitis

2024-7-22

Evidence-based data support strategies for the prevention of Hymenoptera venom anaphylaxis

2024-7-22

Food-triggered anaphylaxis in adults

2024-7-22

Adverse effects of anti-cancer biologics on the ocular surface

2024-7-4

Editorial: pharmacotherapy and evidence-based medicine

2024-6-27

Editorial introductions

2024-6-27

Genetic landscape of atopic dermatitis

2024-6-25

Impact of inflammasomes on the ocular surface

2024-6-21

Treatment options in refractory chronic spontaneous urticaria

2024-6-20

Drug allergy awareness and perspectives with the implementation of the International Classification of Diseases-11

2024-6-14

New evidence in food allergies treatment

2024-5-30

Management and treatment of perioperative hypersensitivity

2024-5-30

Predictive models and applicability of artificial intelligence-based approaches in drug allergy

2024-5-30

Mast cell conditions and drug allergy: when to suspect & how to manage

2024-5-28

State of the art: the treatment of systemic lupus erythematosus

2024-5-20

Greater mechanistic understanding of the cutaneous pathogenesis of Stevens–Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review

2024-5-17

Perioperative anaphylaxis: updates on pathophysiology

2024-5-13

Hereditary angioedema: current therapeutic management and future approaches

2024-5-13

Clinical remission in severe asthma: lights and shadows on an ambitious goal

2024-4-30

Perspectives in the validation of DEFASE: a paradigm shift in food allergy management

2024-4-25

Diagnosis, management and therapeutic options for eosinophilic esophagitis

2024-4-24

Editorial introductions

2024-4-24

Omalizumab is the Columbus egg for food allergies

2024-4-24

Access from healthcare professionals to evidence-based pharmacotherapy in allergy management

2024-4-12

What molecular allergy teaches us about genetics and epidemiology of allergies

2024-4-11

Biological treatments in childhood asthma

2024-4-1

Perspectives in precautionary allergen labelling of prepackaged foods after the FAO/WHO consultation

2024-3-28

Regular consumption following early introduction of allergenic foods and aggressive treatment of eczema are necessary for preventing the development of food allergy in children

2024-3-28

New biologics for food allergy

2024-3-28

Management of food allergy based on oral food challenge

2024-3-27

Role of biologics in severe food allergy

2024-3-27

Precision medicine to personalize medicine in allergic airway disease

2024-3-27

Precision allergy molecular diagnosis applications in food allergy

2024-3-26